瑞戈非尼治疗后转移性结直肠癌预后预测的早期形态学变化

Early morphological change for predicting outcome in metastatic colorectal cancer after regorafenib.

作者信息

Arai Hiroyuki, Miyakawa Kunihisa, Denda Tadamichi, Mizukami Takuro, Horie Yoshiki, Izawa Naoki, Hirakawa Mami, Ogura Takashi, Tsuda Takashi, Sunakawa Yu, Nakajima Takako Eguchi

机构信息

Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan.

Department of Radiology, St. Marianna University School of Medicine, Kawasaki, Japan.

出版信息

Oncotarget. 2017 Nov 30;8(66):110530-110539. doi: 10.18632/oncotarget.22807. eCollection 2017 Dec 15.

BACKGROUND AND OBJECTIVE

It is unclear whether early morphological change (EMC) is a predictive marker for regorafenib in metastatic colorectal cancer (mCRC). Therefore, the present study investigated whether EMC can predict the outcome of mCRC patients receiving regorafenib.

RESULTS

This study evaluated 68 patients. Among 52 patients with lung metastasis, 16 (31%) had cavity formation (CF). The median progression-free survival (PFS) and overall survival (OS) in patients with/without CF were 4.2/2.4 months (p<0.01) and 9.2/6.5 months (p=0.09), respectively. Among 45 patients with liver metastasis, 14 (31%) had active morphological response (MR). The median PFS and OS in patients with/without active MR were 5.3/2.4 months (p<0.01) and 13.6/6.9 months (p=0.02), respectively. Overall, 25 patients (37%) had EMC. The median PFS and OS in patients with/without EMC were 5.3/2.1 months (p<0.01) and 13.3/6.1 months (p<0.01), respectively.

MATERIALS AND METHODS

This retrospective study included mCRC patients with lung and/or liver metastases receiving regorafenib. CF in lung metastasis and MR in liver metastasis were evaluated at the first post-treatment computed tomography scan. EMC was determined as CF and/or active MR. We compared PFS and OS between patients with and those without EMC.

CONCLUSIONS

EMC could be a useful predictive marker for regorafenib in mCRC.

背景与目的

早期形态学改变（EMC）是否为转移性结直肠癌（mCRC）患者使用瑞戈非尼的预测标志物尚不清楚。因此，本研究调查了EMC能否预测接受瑞戈非尼治疗的mCRC患者的预后。

结果

本研究评估了68例患者。在52例有肺转移的患者中，16例（31%）出现空洞形成（CF）。有/无CF患者的中位无进展生存期（PFS）和总生存期（OS）分别为4.2/2.4个月（p<0.01）和9.2/6.5个月（p=0.09）。在45例有肝转移的患者中，14例（31%）出现积极的形态学反应（MR）。有/无积极MR患者的中位PFS和OS分别为5.3/2.4个月（p<0.01）和13.6/6.9个月（p=0.02）。总体而言，25例患者（37%）出现EMC。有/无EMC患者的中位PFS和OS分别为5.3/2.1个月（p<0.01）和13.3/6.1个月（p<0.01）。